Form 4: Shuttle Pharma CFO Granted Over 54,000 Restricted Stock Units

Shuttle Pharmaceuticals Holdings, Inc. CFO Timothy J. Lorber was granted 54,094 Restricted Stock Units with future vesting dates.

Summary

• Timothy J. Lorber, Chief Financial Officer of Shuttle Pharmaceuticals Holdings, Inc. (SHPH), was granted a total of 54,094 Restricted Stock Units (RSUs).
• The first grant consists of 29,240 RSUs, with one-third vesting annually on August 8, 2026, August 8, 2027, and August 8, 2028.
• The second grant consists of 24,854 RSUs, which will vest entirely on February 8, 2026.
• Each RSU represents the contingent right to receive one share of common stock.
• The transaction date for these RSU acquisitions was August 8, 2025.

Sentiment

Score: 7

Explanation: The grant of RSUs to a key executive like the CFO is generally a positive signal, indicating management retention and alignment of interests with shareholders. It's a standard compensation practice.

Positives

• The grant of Restricted Stock Units to the Chief Financial Officer aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• This compensation structure can incentivize long-term commitment and performance from a key executive.

Negatives

• No specific negative information was disclosed in this Form 4 filing, which primarily reports an insider transaction.

Risks

• The value of the granted Restricted Stock Units is subject to the future performance of Shuttle Pharmaceuticals Holdings, Inc.'s common stock.
• Future stock price volatility could impact the ultimate value realized by the recipient upon vesting.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction, beyond the future vesting schedule of the granted RSUs.

Industry Context

The granting of Restricted Stock Units is a common practice in the biotechnology and pharmaceutical industries to compensate and retain key executives, aligning their long-term incentives with company performance and shareholder value creation.

Stakeholder Impact

• Shareholders: The RSU grant aligns the CFO's financial interests with shareholder value, as the value of the RSUs depends on the company's stock price performance.
• Employees: This type of executive compensation can set a precedent or standard for other employee incentive programs, potentially impacting morale and retention.

Key Dates

Keywords

Shuttle Pharmaceuticals Holdings, SHPH, Restricted Stock Units, RSU, Insider Transaction, Executive Compensation, Timothy J. Lorber, CFO, SEC Form 4, Equity Grant